Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from Chardan Capital

Key Points

• Krystal Biotech has been given a "buy" rating by Chardan Capital, with a price target of $219.00, indicating a 46% potential upside from its previous close.
• The stock has a consensus price target of $211.33 and a strong buy consensus rating from analysts, with one hold rating and eight buy ratings issued.
• Krystal Biotech recently reported earnings that missed estimates, with an EPS of $1.20, lower than the projected $1.38.

Chardan Capital reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a $219.00 price target on the stock.

KRYS has been the topic of a number of other research reports. Guggenheim decreased their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, June 24th. Bank of America cut their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Finally, Citigroup restated a "neutral" rating and issued a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $211.33.

Krystal Biotech Price Performance

Krystal Biotech stock traded down $0.22 during mid-day trading on Friday, hitting $152.69. The company's stock had a trading volume of 72,784 shares, compared to its average volume of 316,604. The business has a 50 day moving average price of $138.68 and a 200-day moving average price of $155.67. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $212.06. The stock has a market cap of $4.41 billion, a price-to-earnings ratio of 36.62 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. On average, equities research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This represents a 0.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 49,800 shares of company stock valued at $7,487,943 over the last three months. Insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Krystal Biotech by 173.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company's stock worth $103,764,000 after purchasing an additional 365,304 shares during the period. Nuveen LLC purchased a new position in shares of Krystal Biotech during the 1st quarter worth $42,223,000. Norges Bank purchased a new position in shares of Krystal Biotech during the 4th quarter worth $34,391,000. Braidwell LP grew its holdings in shares of Krystal Biotech by 99.9% during the 1st quarter. Braidwell LP now owns 400,744 shares of the company's stock worth $72,254,000 after purchasing an additional 200,244 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Krystal Biotech during the 1st quarter worth $33,455,000. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).